Medexus Pharmaceuticals Inc (P731.BE)

Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units

TORONTO and CHICAGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX: MDP) (OTCQX: MEDXF), is pleased to announce that it has entered into an agreement with Research Capital Corporation, as sole bookrunner and sole underwriter (the “Underwriter”), pursuant to which the Underwriter has agreed to purchase, on a bought-deal basis, 3,389,900 units of the Company (the “Units”) at a price of C$2.95 per Unit for gross proceeds to the Company of C$10,000